Latvia vs Sur: Diphtheria tetanus toxoid and pertussis third-dose (DTP3)
Latvia
99.0%
in 2025
Sur
80.0%
in 2025
Latvia rank
1st
Sur rank
1st
Diphtheria tetanus toxoid and pertussis third-dose (DTP3) over time
- Latvia
- Sur
How they compare
Latvia currently reports 99.0% against 80.0% in Sur, a difference of 19.0%.
That makes Latvia's figure about 1.2 times Sur's.
The two have swapped places 2 times across 26 shared years of data; in 2000 it was Latvia ahead.
Latvia ranks 1st and Sur ranks 1st of 194 countries.
Latvia has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Latvia | Sur | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 96.4% | 79.5% | 16.9% | Latvia |
| 2010s | 94.6% | 77.3% | 17.3% | Latvia |
| 2020s | 97.0% | 72.0% | 25.0% | Latvia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher diphtheria tetanus toxoid and pertussis third-dose (dtp3), Latvia or Sur?
- Latvia, at 99.0% against 80.0% in Sur as of 2025.
- What is the difference in diphtheria tetanus toxoid and pertussis third-dose (dtp3) between Latvia and Sur?
- 19.0%, with Latvia ahead.
- How many years of comparable data are there for Latvia and Sur?
- 26 years are reported by both, from 2000 to 2025.
- How do Latvia and Sur rank globally for diphtheria tetanus toxoid and pertussis third-dose (dtp3)?
- Latvia ranks 1st and Sur ranks 1st of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Diphtheria tetanus toxoid and pertussis third-dose (DTP3) immunization coverage among 1-year-olds (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.